Roche, Strekin deal

Roche granted Strekin exclusive, worldwide rights to pamapimod (R1503). The p38 mitogen-activated protein kinase ( p38 MAPK) inhibitor has completed two Phase IIb trials to treat rheumatoid arthritis. Strekin said the compound had a favorable safety profile in the trials but, according to Roche, did not reach the “predefined efficacy threshold.” Roche discontinued the development of pamapimod in 2007. Roche will receive an undisclosed upfront payment. ...